The main reason early gene therapy trials failed was (4) activation of oncogenes consequent to integration of the gene.

Option-wise explanation

• (1) Poor integration of a gene in the host genome

  • Early retroviral vectors actually integrated efficiently into host genomes.

  • The problem was not simply “poor integration” but where they integrated.

• (2) Lack of expression of integrated gene in cells

  • In landmark SCID trials, the therapeutic γc gene was expressed well enough to initially correct immune defects.

  • Clinical benefit was seen before adverse events, so lack of expression was not the main cause of failure.

• (3) Degradation of gene inside the cell

  • Once integrated, the proviral DNA is relatively stable; degradation of the gene cassette is not cited as the key reason for trial failures.

• (4) Activation of oncogenes consequent to integration of the gene – correct

  • Retroviral vectors integrated near proto‑oncogenes (e.g., LMO2) and their strong viral enhancers aberrantly activated these oncogenes, leading to clonal expansion and leukemia in some patients.

  • This phenomenon, known as insertional mutagenesis, is the well-documented cause of serious adverse outcomes and early setbacks in clinical gene therapy.

Thus, the application of gene therapy “did not succeed” primarily because of insertional activation of oncogenes, making option (4) the correct choice.